Xinmaikang-mediated mitophagy attenuates atherosclerosis via the PINK1/Parkin signaling pathway

被引:8
|
作者
Cao, Yanhong [1 ,2 ,3 ,4 ,5 ]
Chen, Xin [1 ,2 ,3 ,4 ,5 ]
Pan, Fuqiang [6 ]
Wang, Mingyang [2 ,3 ,4 ,5 ]
Zhuang, Haowen [2 ,3 ,4 ,5 ]
Chen, Jiangna [7 ]
Lu, Lu [2 ,3 ,4 ,5 ]
Wang, Lingjun [2 ,3 ,4 ,5 ]
Wang, Ting [1 ]
机构
[1] Guangzhou Univ Chinese Med, Dongguan Hosp, Dongguan 523000, Peoples R China
[2] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou 510405, Peoples R China
[3] Guangzhou Univ Chinese Med, Clin Med Sch 1, Guangzhou 510405, Peoples R China
[4] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Guangzhou 510405, Peoples R China
[5] Guangzhou Key Lab Chinese Med Prevent & Treatment, Guangzhou 510405, Peoples R China
[6] Liwan Dist Peoples Hosp Guangzhou, Guangzhou 510405, Peoples R China
[7] Sun Yan Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou 510006, Peoples R China
基金
中国国家自然科学基金;
关键词
Atherosclerosis; Mitophagy; PINK1/Parkin; Macrophage; Reactive oxygen specie; MITOCHONDRIAL FISSION;
D O I
10.1016/j.phymed.2023.154955
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Background: The Chinese herbal compound Xinmaikang (XMK) is effective in treating atherosclerosis (AS), although the associated mechanisms of action remain unclear. We hypothesize that XMK increases mitophagy via the PINK1/Parkin signaling pathway and decreases reactive oxygen species (ROS), thus treating AS. Purpose: To explore the above-mentioned mechanisms of action of XMK in AS. Materials and methods: Ultra-performance liquid chromatography assay was performed to clarify the composition of XMK. A 16-week high-fat diet was fed to APOE(-/-) mice to form an AS model. Next, mice were given XMK(0.95 g/kg/d, 1.99 g/kg/d, 3.98 g/kg/d, i.g.) or Atorvastatin(3 mg/kg/d, i.g.) or Rapamycin(4 mg/kg/d, i.p.) or XMK with Mdivi-1(40 mg/kg/d, i.p.) or an equivalent amount of normal saline for 4 weeks. Then mice were examined for AS plaque area, lesion area, collagen fiber, pro-inflammatory cytokines, lipid level, ROS level and mitophagy level. We assessed AS using Oil Red O, hematoxylin and eosin, and Sirius red staining, as well as ROS measurements. Mitophagy was evaluated by transmission electron microscopy, real-time quantitative polymerase chain reaction (RT-qPCR), Western blot, single-cell Western blot, and immunofluorescence staining. In vitro, by oxidizing low-density lipoprotein, formation of RAW264.7 macrophage-derived foam cells induced. we induced foam cell formation in RAW264.7 macrophages. Then cells were incubated with XMK-medicated serum with or without Mdivi-1. We examined foam cell formation, ROS level, mitophagy level in cells. Finally, we knocked down the PINK1, and examined foam cell formation and PINK1/Parkin level in RAW264.7 macrophages. Results: UPLC analysis revealed 102 main ingredients in XMK. In vivo, XMK at medium-dose or high-dose significantly reduced AS plaques, lipids, pro-inflammatory cytokines, and ROS and increased mitophagy. In further study, Single-cell western blot showed that mitophagy level in macrophages sorted from AS mice was lower than the control mice. While XMK improved mitophagy level. In vitro, XMK reduced foam cell formation and ROS and increased mitophagy. When PINK1 was knocked down, XMK's effects on foam cell formation and PINK1/Parkin pathway activation were reduced. Conclusion: The study shows that XMK is effective against AS by mediating macrophage mitophagy via the PINK1/Parkin signaling pathway. For the treatment of AS and drug discovery, it provides an experimental basis and target.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] The activation mechanisms of PINK1 and Parkin during mitophagy
    Komander, David
    JOURNAL OF NEUROCHEMISTRY, 2022, 162 : 15 - 15
  • [22] FoxO1 Promotes Mitophagy in the Podocytes of Diabetic Male Mice via the PINK1/Parkin Pathway
    Li, Wen
    Du, Mengmeng
    Wang, Qingzhu
    Ma, Xiaojun
    Wu, Lina
    Guo, Feng
    Ji, Hongfei
    Huang, Fengjuan
    Qin, Guijun
    ENDOCRINOLOGY, 2017, 158 (07) : 2155 - 2167
  • [23] Parkin and PINK1: much more than mitophagy
    Scarffe, Leslie A.
    Stevens, Daniel A.
    Dawson, Valina L.
    Dawson, Ted M.
    TRENDS IN NEUROSCIENCES, 2014, 37 (06) : 315 - 324
  • [24] FAM72A promotes glioma progression by regulating mitophagy through the Pink1/Parkin signaling pathway
    Zeng, Yibin
    Xiong, Cui
    Tang, Nan
    Wang, Siqi
    Xiong, Zhiyong
    Liang, Tao
    Wang, Qiangping
    Li, Menglong
    Li, Junjun
    JOURNAL OF CANCER, 2023, 14 (06): : 903 - 915
  • [25] Low-dose hexavalent chromium induces mitophagy in rats liver via AMPK related PINK1/Parkin signaling pathway
    Li, N.
    TOXICOLOGY LETTERS, 2024, 399 : S370 - S370
  • [26] Norepinephrine Attenuates Benzalkonium Chloride-Induced Dry Eye Disease by Regulating the PINK1/Parkin Mitophagy Pathway
    Zhao, Han
    Wang, Wushuang
    Yang, Yun
    Feng, Changming
    Lin, Tong
    Gong, Lan
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2024,
  • [27] Paraquat Exposure Induces Pulmonary Cell Mitophagy by Enhancing the PINK1/Parkin Signaling
    Liu Kaixiang
    Zhan Zhipeng
    Gao Wei
    Feng Jie
    Xie Xisheng
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [28] The PINK1/Parkin pathway of mitophagy exerts a protective effect during prion disease
    Ward, Anne
    Jessop, Forrest
    Faris, Robert
    Hollister, Jason
    Shoup, Daniel
    Race, Brent
    Bosio, Catharine M.
    Priola, Suzette A.
    PLOS ONE, 2024, 19 (02):
  • [29] Calcium supplementation attenuates fluoride-induced bone injury via PINK1/Parkin-mediated mitophagy and mitochondrial apoptosis in mice
    Hu, Yingjun
    Li, Yuanyuan
    Li, Meng
    Zhao, Tianrui
    Zhang, Wenhui
    Wang, Yinghui
    He, Yang
    Zhao, Hui
    Li, Haojie
    Wang, Tianyu
    Zhao, Yangfei
    Wang, Jundong
    Wang, Jinming
    JOURNAL OF HAZARDOUS MATERIALS, 2024, 465
  • [30] Erythropoietin Mitigates Diabetic Nephropathy by Restoring PINK1/Parkin-Mediated Mitophagy
    Yi, Xinyao
    Yan, Wenhui
    Guo, Tingli
    Liu, Na
    Wang, Zhuanzhuan
    Shang, Jia
    Wei, Xiaotong
    Cui, Xin
    Sun, Yuzhuo
    Ren, Shuting
    Chen, Lina
    FRONTIERS IN PHARMACOLOGY, 2022, 13